Acadia Pharmaceuticals (ACAD) Non-Current Assets (2010 - 2026)

Acadia Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $509.2 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 94.79% year-over-year to $509.2 million in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 73.03% increase from a year earlier, with the FY2025 full-year figure at $502.1 million, up 101.29% from the prior year.
• Non-Current Assets grew to $509.2 million in Q1 2026 per ACAD's latest filing, from $502.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $509.2 million in Q1 2026 and bottomed at $79.9 million in Q4 2022.
• The 5-year median for Non-Current Assets is $179.8 million (2024), against an average of $205.1 million.
• Across the five-year window, Non-Current Assets dropped 2.95% in 2022 and soared 101.29% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $79.9 million in 2022, then surged by 66.3% to $132.8 million in 2023, then jumped by 87.79% to $249.4 million in 2024, then surged by 101.29% to $502.1 million in 2025, then gained by 1.42% to $509.2 million in 2026.
• Per Business Quant, the three latest ACAD Non-Current Assets figures stand at $509.2 million (Q1 2026), $502.1 million (Q4 2025), and $254.3 million (Q3 2025).